BioCryst Enterprise Value vs Net Income Analysis
BCRX Stock | USD 4.21 0.17 3.88% |
BioCryst Pharmaceuticals financial indicator trend analysis is way more than just evaluating BioCryst Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioCryst Pharmaceuticals is a good investment. Please check the relationship between BioCryst Pharmaceuticals Enterprise Value and its Net Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.
Enterprise Value vs Net Income
Enterprise Value vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioCryst Pharmaceuticals Enterprise Value account and Net Income. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between BioCryst Pharmaceuticals' Enterprise Value and Net Income is -0.25. Overlapping area represents the amount of variation of Enterprise Value that can explain the historical movement of Net Income in the same time period over historical financial statements of BioCryst Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of BioCryst Pharmaceuticals' Enterprise Value and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Enterprise Value of BioCryst Pharmaceuticals are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Enterprise Value i.e., BioCryst Pharmaceuticals' Enterprise Value and Net Income go up and down completely randomly.
Correlation Coefficient | -0.25 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Enterprise Value
Enterprise Value (or EV) is usually referred to as BioCryst Pharmaceuticals theoretical takeover price. In the event of an acquisition, an acquirer would have to take on BioCryst Pharmaceuticals debt, but would also pocket its cash. Enterprise Value is more accurate representation of BioCryst Pharmaceuticals value than its market capitalization because it takes into account all of BioCryst Pharmaceuticals existing debt. A measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization that includes the market capitalization, plus total debt, minority interest and preferred shares, minus total cash and cash equivalents.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in BioCryst Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of BioCryst Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from BioCryst Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioCryst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.At this time, BioCryst Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 1.9 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 324.9 K in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 327.6M | 412.7M | 428.8M | 450.2M | Cost Of Revenue | 7.3M | 6.6M | 6.3M | 9.2M |
BioCryst Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
BioCryst Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioCryst Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 175.3M | 334.7M | 588.2M | 550M | 517.0M | 542.8M | |
Short Long Term Debt Total | 84.7M | 124.7M | 593.2M | 741.5M | 848.7M | 891.1M | |
Other Current Liab | 36.3M | 55.6M | 72.7M | 87.6M | 102.9M | 108.0M | |
Total Current Liabilities | 92.3M | 105.7M | 103.7M | 105.5M | 150.0M | 157.5M | |
Total Stockholder Equity | (840.6M) | (1.0B) | (1.2B) | (1.5B) | (455.5M) | (432.8M) | |
Property Plant And Equipment Net | 7.3M | 7.1M | 8.7M | 15.4M | 21.0M | 22.0M | |
Net Debt | (29.5M) | (147.4M) | 88.8M | 436.7M | 736.3M | 773.1M | |
Retained Earnings | (840.6M) | (1.0B) | (1.2B) | (1.5B) | (1.7B) | (1.6B) | |
Accounts Payable | 14.0M | 18.7M | 27.8M | 14.4M | 20.9M | 21.9M | |
Cash | 114.2M | 272.1M | 504.4M | 304.8M | 112.4M | 65.7M | |
Non Current Assets Total | 10.9M | 10.9M | 22.0M | 33.5M | 21.0M | 24.6M | |
Cash And Short Term Investments | 136.2M | 300.4M | 514.4M | 442.4M | 390.8M | 410.3M | |
Common Stock Shares Outstanding | 115.6M | 167.3M | 179.1M | 185.9M | 192.2M | 201.8M | |
Liabilities And Stockholders Equity | (703.6M) | (669.5M) | (512.4M) | (610.0M) | 517.0M | 542.8M | |
Non Current Liabilities Total | 44.7M | 248.3M | 591.4M | 739.1M | 822.5M | 863.6M | |
Other Current Assets | 4.4M | 5.5M | 10.0M | 12.6M | 19.5M | 20.5M | |
Other Stockholder Equity | (1.6M) | (1.8M) | (2.0M) | (1.9M) | 1.2B | 1.3B | |
Total Liab | 137.0M | 354.0M | 695.1M | 844.6M | 972.5M | 1.0B | |
Property Plant And Equipment Gross | 7.3M | 7.1M | 8.7M | 25.0M | 19.1M | 20.1M | |
Total Current Assets | 164.3M | 323.8M | 566.1M | 516.5M | 496.0M | 520.8M | |
Accumulated Other Comprehensive Income | 39K | 3K | 177K | 26K | 1.3M | 1.4M | |
Short Term Debt | 40.0M | 31.2M | 1.8M | 2.4M | 26.2M | 27.5M | |
Non Currrent Assets Other | 3.6M | 3.8M | 6.5M | (33.5M) | 12.0M | 7.6M | |
Common Stock Total Equity | 1.1M | 1.5M | 1.8M | 1.8M | 2.1M | 2.2M | |
Short Term Investments | 22.1M | 28.2M | 3.2M | 119.5M | 278.3M | 292.3M | |
Common Stock | 1.5M | 1.8M | 1.8M | 1.9M | 2.1M | 2.2M | |
Current Deferred Revenue | 2.1M | 150K | 1.4M | 1.2M | 1.1M | 1.0M | |
Property Plant Equipment | 7.3M | 7.1M | 15.2M | 15.4M | 17.7M | 18.6M | |
Other Assets | 2.0M | 978K | 588.2M | 550M | 632.5M | 664.1M | |
Net Receivables | 22.1M | 8.6M | 29.4M | 50.6M | 57.0M | 59.8M | |
Inventory | 1.6M | 7.0M | 15.8M | 27.5M | 28.7M | 30.1M | |
Net Tangible Assets | 82.9M | 109.3M | (147.0M) | (294.6M) | (265.1M) | (251.9M) | |
Long Term Debt | 41.3M | 119.7M | 585.5M | 733.3M | 811.3M | 851.8M | |
Retained Earnings Total Equity | (732.0M) | (840.6M) | (1.0B) | (1.2B) | (1.1B) | (1.0B) | |
Long Term Debt Total | 28.1M | 41.3M | 119.7M | 136.1M | 156.5M | 164.3M | |
Capital Surpluse | 780.4M | 877.3M | 1.0B | 1.1B | 1.3B | 745.7M |
Pair Trading with BioCryst Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioCryst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against BioCryst Stock
0.74 | ACB | Aurora Cannabis Trending | PairCorr |
0.73 | CGC | Canopy Growth Corp Trending | PairCorr |
0.66 | XFOR | X4 Pharmaceuticals Earnings Call Next Week | PairCorr |
0.62 | NRSNW | NeuroSense Therapeutics | PairCorr |
0.58 | ELEV | Elevation Oncology Earnings Call Next Week | PairCorr |
The ability to find closely correlated positions to BioCryst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioCryst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioCryst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioCryst Pharmaceuticals to buy it.
The correlation of BioCryst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioCryst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioCryst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for BioCryst Stock analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
CEOs Directory Screen CEOs from public companies around the world | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 1.724 | Quarterly Revenue Growth 0.174 | Return On Assets (0.12) | Return On Equity (19.25) |
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.